Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
1.180
-0.065 (-5.22%)
At close: Sep 17, 2025, 4:00 PM EDT
1.180
0.00 (0.00%)
Pre-market: Sep 18, 2025, 7:13 AM EDT
Ernexa Therapeutics Revenue
Ernexa Therapeutics had revenue of $488.00K in the twelve months ending June 30, 2025, up 201.23% year-over-year. In the year 2024, Ernexa Therapeutics had annual revenue of $582.00K with 755.88% growth.
Revenue (ttm)
$488.00K
Revenue Growth
+201.23%
P/S Ratio
7.02
Revenue / Employee
$81,333
Employees
6
Market Cap
9.05M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 582.00K | 514.00K | 755.88% |
Dec 31, 2023 | 68.00K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ERNA News
- 22 hours ago - Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research - GlobeNewsWire
- 7 days ago - Ernexa Therapeutics Provides Update on Operational Excellence and Performance - GlobeNewsWire
- 14 days ago - Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 3 months ago - Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development - GlobeNewsWire
- 3 months ago - Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement - GlobeNewsWire
- 3 months ago - Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split - GlobeNewsWire
- 4 months ago - Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 - GlobeNewsWire